Anirban Maitra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1400747/publications.pdf

Version: 2024-02-01

228	43,353	5268	2280
papers	citations	83 h-index	200 g-index

241	241	241	45301
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science, 2008, 321, 1801-1806.	12.6	3,755
2	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	27.8	2,700
3	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 2003, 4, 437-450.	16.8	2,150
4	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	27.8	2,132
5	A draft map of the human proteome. Nature, 2014, 509, 575-581.	27.8	1,948
6	Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell, 2014, 25, 719-734.	16.8	1,892
7	EMT and Dissemination Precede Pancreatic Tumor Formation. Cell, 2012, 148, 349-361.	28.9	1,746
8	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	27.8	1,741
9	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science, 2017, 357, 1156-1160.	12.6	1,059
10	Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell, 2019, 178, 795-806.e12.	28.9	830
11	Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. Science Translational Medicine, 2011, 3, 92ra66.	12.4	703
12	Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. ELife, 2016, 5, e10250.	6.0	681
13	Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers. Cancer Research, 2007, 67, 2187-2196.	0.9	647
14	Pancreatic Cancer. Annual Review of Pathology: Mechanisms of Disease, 2008, 3, 157-188.	22.4	634
15	Genomic alterations in cultured human embryonic stem cells. Nature Genetics, 2005, 37, 1099-1103.	21.4	592
16	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21188-21193.	7.1	585
17	Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia. Gastroenterology, 2012, 142, 730-733.e9.	1.3	568
18	Early Detection of Pancreatic Cancer: Opportunities and Challenges. Gastroenterology, 2019, 156, 2024-2040.	1.3	476

#	Article	IF	Citations
19	Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 487-505.	17.8	458
20	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	7.1	438
21	The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes and Development, 2010, 24, 2383-2388.	5.9	426
22	Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development, 2016, 30, 355-385.	5.9	416
23	An In vivo Platform for Translational Drug Development in Pancreatic Cancer. Clinical Cancer Research, 2006, 12, 4652-4661.	7.0	407
24	Pathology of Genetically Engineered Mouse Models of Pancreatic Exocrine Cancer: Consensus Report and Recommendations. Cancer Research, 2006, 66, 95-106.	0.9	401
25	Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations. Cancer Discovery, 2014, 4, 905-913.	9.4	395
26	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature Communications, 2015, 6, 7686.	12.8	393
27	Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray. Modern Pathology, 2003, 16, 902-912.	5.5	363
28	Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18913-18918.	7.1	358
29	Oncogenic Kras Activates a Hematopoietic-to-Epithelial IL-17 Signaling Axis in Preinvasive Pancreatic Neoplasia. Cancer Cell, 2014, 25, 621-637.	16.8	324
30	Targeted nextâ€generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. Journal of Pathology, 2014, 233, 217-227.	4.5	308
31	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2541-2556.	1.6	302
32	DCLK1 Marks a Morphologically Distinct Subpopulation of Cells With Stem Cell Properties in Preinvasive Pancreatic Cancer. Gastroenterology, 2014, 146, 245-256.	1.3	277
33	Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology, 2019, 156, 108-118.e4.	1.3	270
34	Pancreatic cancer. Current Problems in Cancer, 2002, 26, 176-275.	2.0	268
35	Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. Clinical Cancer Research, 2019, 25, 2194-2205.	7.0	268
36	Precursors to Invasive Pancreatic Cancer. Advances in Anatomic Pathology, 2005, 12, 81-91.	4.3	266

#	Article	IF	Citations
37	Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. American Journal of Surgical Pathology, 2006, 30, 1067-76.	3.7	261
38	Early Detection of Sporadic Pancreatic Cancer. Pancreas, 2015, 44, 693-712.	1.1	255
39	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. American Journal of Pathology, 2014, 184, 1280-1286.	3.8	250
40	Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer. Molecular Cancer Therapeutics, 2011, 10, 3-8.	4.1	238
41	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1692-1697.	7.1	237
42	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Ca-A Cancer Journal for Clinicians, 2020, 70, 375-403.	329.8	237
43	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology, 2019, 156, 2242-2253.e4.	1.3	224
44	Interleukin-17â€“induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. Journal of Experimental Medicine, 2020, 217, .	8.5	219
45	The Human MitoChip: A High-Throughput Sequencing Microarray for Mitochondrial Mutation Detection. Genome Research, 2004, 14, 812-819.	5.5	218
46	Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature, 2017, 542, 119-123.	27.8	209
47	Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clinical Cancer Research, 2009, 15, 7737-7743.	7.0	195
48	Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell, 2016, 29, 75-89.	16.8	191
49	Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer. Molecular Cancer Therapeutics, 2010, 9, 2255-2264.	4.1	184
50	In vivo endomicroscopy improves detection of Barrett's esophagusâ€“related neoplasia: a multicenter international randomized controlled trial (with video). Gastrointestinal Endoscopy, 2014, 79, 211-221.	1.0	183
51	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	1.3	174
52	Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. JCI Insight, 2019, 4, .	5.0	169
53	Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Annals of Oncology, 2016, 27, 635-641.	1.2	166
54	Molecular pathogenesis of pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 211-226.	2.4	161

#	Article	IF	Citations
55	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2017, 35, 2324-2328.	1.6	160
56	Update on pancreatic intraepithelial neoplasia. International Journal of Clinical and Experimental Pathology, 2008, 1, 306-16.	0.5	159
57	Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Annals of Surgical Oncology, 2013, 20, 3802-3808.	1.5	158
58	Inhibiting the Cyclin-Dependent Kinase CDK5 Blocks Pancreatic Cancer Formation and Progression through the Suppression of Ras-Ral Signaling. Cancer Research, 2010, 70, 4460-4469.	0.9	140
59	Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Cancer Research, 2015, 75, 3355-3364.	0.9	129
60	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature, 2019, 568, 410-414.	27.8	129
61	miR-181c Regulates the Mitochondrial Genome, Bioenergetics, and Propensity for Heart Failure In Vivo. PLoS ONE, 2014, 9, e96820.	2.5	128
62	Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports, 2016, 6, 35848.	3.3	127
63	Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. Cancer Research, 2018, 78, 246-255.	0.9	127
64	Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer. Cancer Immunology Research, 2017, 5, 182-190.	3.4	126
65	Immunohistochemical Validation of a Novel Epithelial and a Novel Stromal Marker of Pancreatic Ductal Adenocarcinoma Identified by Global Expression Microarrays. American Journal of Clinical Pathology, 2002, 118, 52-59.	0.7	124
66	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Journal of Gastrointestinal Surgery, 2017, 21, 164-174.	1.7	124
67	Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nature Communications, 2019, 10, 254.	12.8	120
68	Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Cancer Discovery, 2020, 10, 608-625.	9.4	119
69	A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice. Gastroenterology, 2014, 146, 1784-1794.e6.	1.3	118
70	Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell, 2022, 40, 153-167.e11.	16.8	118
71	METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis. Cell, 2019, 176, 491-504.e21.	28.9	117
72	Quantitative imaging to evaluate malignant potential of IPMNs. Oncotarget, 2016, 7, 85776-85784.	1.8	115

#	Article	IF	Citations
73	InÂVivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Reports, 2016, 16, 133-147.	6.4	114
74	Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Gastroenterology, 2018, 155, 210-223.e3.	1.3	114
75	Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. International Journal of Cancer, 2013, 132, 785-794.	5.1	111
76	Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Nature Metabolism, 2020, 2, 775-792.	11.9	110
77	Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 199-208.	17.8	106
78	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature, 2017, 542, 362-366.	27.8	105
79	Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. British Journal of Cancer, 2020, 122, 498-505.	6.4	105
80	Loss of Stk11/Lkb1 Expression in Pancreatic and Biliary Neoplasms. Modern Pathology, 2003, 16, 686-691.	5.5	104
81	Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biology and Therapy, 2011, 12, 598-609.	3.4	103
82	Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. ELife, 2019, 8, .	6.0	103
83	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science, 2021, 373, eabj0486.	12.6	99
84	Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Genes and Development, 2016, 30, 233-247.	5.9	97
85	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology, 2021, 160, 362-377.e13.	1.3	90
86	Translational advances in pancreatic ductal adenocarcinoma therapy. Nature Cancer, 2022, 3, 272-286.	13.2	90
87	Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Science Signaling, 2015, 8, ra77.	3.6	89
88	Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Clinical Cancer Research, 2015, 21, 1944-1950.	7.0	85
89	Increased expression and processing of the Alzheimer amyloid precursor protein in pancreatic cancer may influence cellular proliferation. Cancer Research, 2003, 63, 7032-7.	0.9	85
90	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2017, 152, 1048.	4.3	82

#	Article	IF	Citations
91	Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Gastroenterology, 2020, 159, 306-319.e12.	1.3	82
92	Evolution of cellular morpho-phenotypes in cancer metastasis. Scientific Reports, 2016, 5, 18437.	3.3	81
93	Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials, 2018, 159, 215-228.	11.4	81
94	A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 372-379.	6.3	79
95	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	6.4	78
96	Recent insights into the biology of pancreatic cancer. EBioMedicine, 2020, 53, 102655.	6.1	78
97	A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothened Antagonists. Molecular Cancer Therapeutics, 2012, 11, 165-173.	4.1	77
98	Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology, 2021, 160, 1373-1383.e6.	1.3	77
99	Treatment of Pancreatic Cancer Patientâ€“Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. Clinical Cancer Research, 2017, 23, 5639-5647.	7.0	76
100	A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2018, 24, 5883-5894.	7.0	76
101	Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. Journal of the National Cancer Institute, 2015, 107, .	6.3	72
102	Artificial Intelligence and Early Detection of Pancreatic Cancer. Pancreas, 2021, 50, 251-279.	1.1	71
103	The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLoS ONE, 2017, 12, e0180181.	2.5	68
104	Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clinical Cancer Research, 2003, 9, 5988-95.	7.0	67
105	Heterogeneity and Targeting of Pancreatic Cancer Stem Cells. Clinical Cancer Research, 2012, 18, 4277-4284.	7.0	65
106	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell, 2019, 35, 204-220.e9.	16.8	62
107	Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. , 2020, 8, e000587.		62
108	Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. Gastroenterology, 2022, 162, 2018-2031.	1.3	62

#	Article	IF	Citations
109	GNASR201C Induces Pancreatic Cystic Neoplasms in Mice That Express Activated KRAS by Inhibiting YAP1 Signaling. Gastroenterology, 2018, 155, 1593-1607.e12.	1.3	61
110	Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 280-289.	7.0	59
111	A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2015, 468, 525-532.	2.1	59
112	Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell, 2018, 33, 752-769.e8.	16.8	58
113	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Research, 2018, 28, 432-447.	5.5	58
114	Pancreatic Cancer Database. Cancer Biology and Therapy, 2014, 15, 963-967.	3.4	57
115	Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 (APE1/Ref-1) Redox Function Negatively Regulates NRF2. Journal of Biological Chemistry, 2015, 290, 3057-3068.	3.4	57
116	Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract. Genes, 2020, 11, 645.	2.4	57
117	Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. Clinical Cancer Research, 2021, 27, 5912-5921.	7.0	57
118	Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. Molecular Cancer Therapeutics, 2015, 14, 1532-1539.	4.1	54
119	Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling. Cancer Discovery, 2018, 8, 386-388.	9.4	54
120	Heterogeneity of Pancreatic Cancer Metastases in a Single Patient Revealed by Quantitative Proteomics. Molecular and Cellular Proteomics, 2014, 13, 2803-2811.	3.8	52
121	Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. Genome Research, 2017, 27, 1830-1842.	5.5	51
122	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer, 2016, 122, 2671-2679.	4.1	49
123	SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. Cancer Cell, 2020, 37, 834-849.e13.	16.8	48
124	Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas, 2017, 46, 1180-1187.	1.1	47
125	The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology, 2016, 68, 210-220.	2.9	46
126	YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI Insight, 2019, 4, .	5.0	46

#	Article	IF	Citations
127	EMT: Matter of Life or Death?. Cell, 2016, 164, 840-842.	28.9	45
128	Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. Laboratory Investigation, 2015, 95, 43-55.	3.7	44
129	Direct Interactions With Cancer-Associated Fibroblasts Lead to Enhanced Pancreatic Cancer Stem Cell Function. Pancreas, 2019, 48, 329-334.	1.1	44
130	Roles and Regulations of TET Enzymes in Solid Tumors. Trends in Cancer, 2021, 7, 635-646.	7.4	43
131	Pancreatic Intraepithelial Neoplasia and Pancreatic Tumorigenesis: Of Mice and Men. Archives of Pathology and Laboratory Medicine, 2009, 133, 375-381.	2.5	43
132	Metabolic Imaging of Pancreatic Ductal Adenocarcinoma Detects Altered Choline Metabolism. Clinical Cancer Research, 2015, 21, 386-395.	7.0	42
133	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 7263-7275.	7.0	41
134	Single-cell RNA sequencing in pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 451-452.	17.8	40
135	Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. British Journal of Cancer, 2016, 115, 442-453.	6.4	39
136	Subtyping Pancreatic Cancer. Cancer Cell, 2015, 28, 411-413.	16.8	38
137	Characterization and Comparison of GITR Expression in Solid Tumors. Clinical Cancer Research, 2019, 25, 6501-6510.	7.0	37
138	Pancreatitis and Pancreatic Cancer. Gastroenterology, 2019, 156, 1937-1940.	1.3	37
139	Obesity, Intrapancreatic Fatty Infiltration, and Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 3369-3371.	7.0	36
140	A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).. Journal of Clinical Oncology, 2014, 32, 257-257.	1.6	36
141	Imagingâ€based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer, 2018, 124, 1701-1709.	4.1	35
142	APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Nature Cancer, 2021, 2, 1338-1356.	13.2	35
143	Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Science Translational Medicine, 2018, 10, .	12.4	33
144	Identification and Analysis of Precursors to Invasive Pancreatic Cancer. , 2005, 103, 001-014.		32

#	Article	IF	Citations
145	Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Physical Biology, 2014, 11, 065002.	1.8	32
146	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nature Communications, 2021, 12, 4626.	12.8	31
147	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nature Biotechnology, 2022, 40, 1624-1633.	17.5	31
148	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Annals of Surgical Oncology, 2017, 24, 2031-2039.	1.5	30
149	A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination. Laboratory Investigation, 2019, 99, 1233-1244.	3.7	30
150	p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. Cancer Research, 2016, 76, 3351-3363.	0.9	29
151	A Functional Spatial Analysis Platform for Discovery of Immunological Interactions Predictive of Low-Grade to High-Grade Transition of Pancreatic Intraductal Papillary Mucinous Neoplasms. Cancer Informatics, 2018, 17, 117693511878288.	1.9	29
152	Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth. Oncotarget, 2014, 5, 2575-2587.	1.8	29
153	Isolation and mutational assessment of pancreatic cancer extracellular vesicles using a microfluidic platform. Biomedical Microdevices, 2020, 22, 23.	2.8	28
154	A new mouse model of pancreatic cancer: PTEN gets its Akt together. Cancer Cell, 2005, 8, 171-172.	16.8	27
155	Combining Hyperpolarized Real-Time Metabolic Imaging and NMR Spectroscopy To Identify Metabolic Biomarkers in Pancreatic Cancer. Journal of Proteome Research, 2019, 18, 2826-2834.	3.7	27
156	Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. Cancer Research, 2019, 79, 2327-2338.	0.9	27
157	Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. British Journal of Cancer, 2021, 124, 1970-1977.	6.4	26
158	Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. Gastroenterology, 2022, 162, 1303-1318.e18.	1.3	26
159	High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. Cancer Prevention Research, 2018, 11, 679-686.	1.5	25
160	Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. Laboratory Investigation, 2021, 101, 177-192.	3.7	25
161	PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. Cancer Discovery, 2021, 11, 1774-1791.	9.4	25
162	Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. PLoS ONE, 2017, 12, e0171985.	2.5	25

#	Article	IF	Citations
163	Disputed Paternity: The Uncertain Ancestry of Pancreatic Ductal Neoplasia. Cancer Cell, 2012, 22, 701-703.	16.8	24
164	Molecular envoys pave the way for pancreatic cancer to invade the liver. Nature, 2019, 567, 181-182.	27.8	24
165	Liquid biopsies in pancreatic cancer. Expert Review of Anticancer Therapy, 2019, 19, 869-878.	2.4	24
166	p120 Catenin is required for normal tubulogenesis but not epithelial integrity in developing mouse pancreas. Developmental Biology, 2015, 399, 41-53.	2.0	23
167	A Phase I Study of Dinaciclib in Combination With MKâ€2206 in Patients With Advanced Pancreatic Cancer. Clinical and Translational Science, 2020, 13, 1178-1188.	3.1	23
168	Loss of ARID1A Promotes Epithelialâ€“Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. Cancer Research, 2021, 81, 332-343.	0.9	22
169	Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Cancer Discovery, 2022, 12, 2330-2349.	9.4	22
170	Dynamic changes during the treatment of pancreatic cancer. Oncotarget, 2018, 9, 14764-14790.	1.8	21
171	Plasma-Derived Extracellular Vesicles Convey Protein Signatures That Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas. Cancers, 2020, 12, 1147.	3.7	20
172	Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples. Clinical Cancer Research, 2021, 27, 1082-1093.	7.0	20
173	Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. PLoS ONE, 2016, 11, e0152300.	2.5	20
174	PARP inhibition â€” opportunities in pancreatic cancer. Nature Reviews Clinical Oncology, 2019, 16, 595-596.	27.6	19
175	Of scientists and tweets. Nature Reviews Cancer, 2019, 19, 479-480.	28.4	19
176	Computed Tomographyâ€“Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precision Oncology, 2019, 3, 1-15.	3.0	19
177	The emerging roles of F-box proteins in pancreatic tumorigenesis. Seminars in Cancer Biology, 2016, 36, 88-94.	9.6	18
178	Overexpression of ankyrin1 promotes pancreatic cancer cell growth. Oncotarget, 2016, 7, 34977-34987.	1.8	18
179	Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas. Journal of Pathology, 2017, 243, 271-272.	4.5	17
180	A microfluidic device for label-free isolation of tumor cell clusters from unprocessed blood samples. Biomicrofluidics, 2019, 13, 044111.	2.4	17

#	Article	IF	Citations
181	Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective. Surgery, 2020, 168, 601-609.	1.9	17
182	Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer. Cancer Prevention Research, 2021, 14, 729-740.	1.5	16
183	Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Pancreatology, 2021, 21, 942-949.	1.1	16
184	Loss of HNF6 expression correlates with human pancreatic cancer progression. Laboratory Investigation, 2014, 94, 517-527.	3.7	15
185	Pancreatic Cancer Genomics 2.0: Profiling Metastases. Cancer Cell, 2017, 31, 309-310.	16.8	15
186	Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nature Communications, 2020, 11, 5332.	12.8	15
187	CES2 sustains HNF4Î± expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Molecular Metabolism, 2022, 56, 101426.	6.5	14
188	Early Detection of Pancreatic Intraepithelial Neoplasias (PanINs) in Transgenic Mouse Model by Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy. International Journal of Molecular Sciences, 2020, 21, 3722.	4.1	13
189	Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution. Nature Communications, 2022, 13, .	12.8	13
190	Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis. Cancers, 2020, 12, 2695.	3.7	12
191	Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Research, 2019, 17, 929-936.	3.4	11
192	Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Cancers, 2020, 12, 3656.	3.7	11
193	Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer. Journal of Biological Chemistry, 2020, 295, 2348-2358.	3.4	11
194	Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRAS^{G12D}siRNA in patients with metastatic pancreatic cancer harboring a KRAS^{G12D} mutation.. Journal of Clinical Oncology, 2022, 40, TPS633-TPS633.	1.6	11
195	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
196	Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception. Clinical Cancer Research, 2022, 28, 1938-1947.	7.0	11
197	Detection of Pancreatic Cancerâ€“Induced Cachexia Using a Fluorescent Myoblast Reporter System and Analysis of Metabolite Abundance. Cancer Research, 2016, 76, 1441-1450.	0.9	10
198	Brain metabolites in cholinergic and glutamatergic pathways are altered by pancreatic cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1487-1500.	7.3	10

#	Article	IF	Citations
199	Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early Detection. Frontiers in Oncology, 2020, 10, 596931.	2.8	10
200	Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochemical and Biophysical Research Communications, 2014, 443, 635-640.	2.1	9
201	CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precision Oncology, 2020, 4, 426-436.	3.0	9
202	Pancreatic Safety of Newer Incretin-Based Therapies: Are the "-tides" Finally Turning?. Diabetes, 2014, 63, 2219-2221.	0.6	8
203	Molecular and Genetic Basis of Pancreatic Carcinogenesis. Surgical Oncology Clinics of North America, 2016, 25, 227-238.	1.5	8
204	First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 619-627.	1.5	8
205	Upfront molecular profiling of pancreatic cancer patients â€“ An idea whose time has come. Pancreatology, 2020, 20, 391-393.	1.1	8
206	Hear Pancreatic Cancer Stem Cells ROR. Cell, 2019, 177, 516-518.	28.9	7
207	Early detection of pancreatic cancer: current state and future opportunities. Current Opinion in Gastroenterology, 2021, 37, 532-538.	2.3	6
208	Quality of life impact of EUS in patients at risk for developing pancreatic cancer. Endoscopic Ultrasound, 2020, 9, 53.	1.5	6
209	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer and Metastasis Reviews, 2022, 41, 147-172.	5.9	6
210	Adequacy evaluation and use of pancreatic adenocarcinoma specimens for nextâ€generation sequencing acquired by endoscopic ultrasoundâ€“guided FNA and FNB. Cancer Cytopathology, 2022, 130, 275-283.	2.4	6
211	Itâ€™s a SMAD/SMAD World. Cell, 2015, 161, 1245-1246.	28.9	5
212	Hyperpolarized Magnetic Resonance and Artificial Intelligence: Frontiers of Imaging in Pancreatic Cancer. JMIR Medical Informatics, 2021, 9, e26601.	2.6	5
213	Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis. JMIR Cancer, 2022, 8, e31388.	2.4	5
214	A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling. Gastroenterology, 2015, 149, 1685-1688.	1.3	4
215	KrÃ¼ppel-Like Factor 4 Promotes Pancreatic Acinar-to-Ductal Metaplasia and Tumor Initiation. Pancreas, 2017, 46, 139-142.	1.1	4
216	Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology, 2021, 21, 200-207.	1.1	4

#	Article	IF	Citations
217	HIF2 Regulates Intestinal Wnt5a Expression. Frontiers in Oncology, 2021, 11, 769385.	2.8	4
218	Extrahepatic Biliary Atresia Demonstrates Abnormal Persistence of HES1 Protein in Neonatal Biliary Epithelium: An Immunohistochemical Study. Pediatric and Developmental Pathology, 2006, 9, 98-102.	1.0	3
219	GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Pancreatology, 2021, 21, 1378-1385.	1.1	3
220	Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers, 2021, 13, 5709.	3.7	3
221	Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2022, 40, TPS4188-TPS4188.	1.6	3
222	Bringing Pathobiology into Focus. Laboratory Investigation, 2006, 86, 632-632.	3.7	2
223	Introduction of #PancChat: A novel Twitter platform to inform and engage the pancreatic cancer community.. Journal of Clinical Oncology, 2018, 36, 242-242.	1.6	2
224	Heterogeneity of Tumor Exosomes â€“ Role in Precision Medicine. , 2018, , 59-67.		1
225	Membrane-bound MMP-14 protease-activatable adeno-associated viral vectors for gene delivery to pancreatic tumors. Gene Therapy, 2021, , .	4.5	1
226	A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Journal of Gastrointestinal Oncology, 2017, 8, 925-935.	1.4	0
227	Improvement in lung health in PCD. Journal of Paediatrics and Child Health, 2021, , .	0.8	0
228	Implementation of a Video-based Remote Germline Testing for Individuals With Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2022, 163, 316-318.e1.	1.3	0